The market for non-insulin diabetes treatments has experienced strong growth over the past decade, averaging 9.5 per cent over the past five years. Epidemiology and unmet need have combined to generate demand for new product classes. The first of these, the DPP-IV class, is dominated by Merck & Co’s Januvia®, but further launches are lining up in another major new class, the SGLT-2s. Given the similarities in the competitive characteristics of this new class compared to the DPP-IVs, IMS believes there may be significant learning opportunities from the successes and failures of recent oral diabetes agent launches.
08 August, 2012
A unique feature of pharmacology as a scientific discipline is that it furnishes the tools to quantify complex behaviors of drugs in complete physiological systems in terms affinity and efficacy. The history of pharmacology, as applied to new drug discovery, has been heavily weighted toward null methods to determine drug properties in the absence of detailed knowledge of the physiological processes involved in yielding pharmacologic response. This process began with animal isolated tissues and now has come full circle with label-free human cell culture assays. However, the circle is now at a more advantageous point for drug discovery than it has ever been.
06 August, 2012
The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
01 August, 2012